SCHEMBL2961336

SCHEMBL2961336

O=C(Oc1nn(C(=O)N2CCN(c3ccccc3)CC2)c2cc(F)ccc12)N1CCN(c2ccccc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.52
FAAH O00519 5/20 0.45
MGLL Q99685 3/20 0.45
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.44
RECQL P46063 1/20 0.44
MAPT P10636 1/20 0.41
AKR1C3 P42330 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPK1 P28482 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
GLA P06280 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16242493 0.88 FAAH (0.42) ALOX15FAAHMGLLALDH1A1LMNA
SCHEMBL2965248 0.83 NPC1 (0.36) ALOX15ALDH1A1AKR1C3SMN1; SMN2
SCHEMBL2955527 0.81 GAA (0.43) FAAHALDH1A1CYP2C9CYP2C19SMN1; SMN2
SCHEMBL2956860 0.79 SPR (0.36) FAAH
SCHEMBL1574085 0.77 ALOX15 (0.54) ALOX15FAAHALDH1A1LMNARECQL
SCHEMBL2954699 0.72 LMNA (0.49) ALOX15ALDH1A1LMNARECQLMAPT
SCHEMBL2958195 0.72 PRMT5 (0.38) AKR1C3CYP2C19
SCHEMBL4837047 0.71 NPC1 (0.36) ALDH1A1
SCHEMBL1573644 0.70 RAB9A (0.39) ALDH1A1MAPTMAPK1SMN1; SMN2HTT
SCHEMBL4828449 0.68 SPR (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937648-B1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI SA (FR) 2014-11-26 EP disclosed
US-8357698-B2 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI (FR) 2013-01-22 US disclosed
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2010-11-11 US disclosed
US-7772268-B2 inhibitors of hormone-sensitive lipase and/or endothelial lipase; for treatment of diabetes mellitus, dyslipidemia and atherosclerotic disorders SANOFI-AVENTIS (FR) 2010-08-10 US disclosed
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL ALOX15 286/4885FAAH 133/4885MGLL 3/4885
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL ALOX15 286/4885FAAH 133/4885MGLL 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.